ArticleMolecular therapy : the journal of the American Society of Gene Therapy2021
Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 42 citations in OpenAlex.
- Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal transduction and targeted therapy · 2026Review
- BATF3 regulates differentiation of CD8Life science alliance · 2026Article
- Impact of Glycine-Serine Linker on Target Antigen Binding and Subsequent CD37CAR-T Performance.International journal of molecular sciences · 2026Article
- CD79A/CD40 intracellular domain uses a 4-1BB-like metabolic pathway driven by cholesterol biosynthesis.Journal for immunotherapy of cancer · 2026Article
- Fusion protein-mediated costimulation in engineered T cells: from intrinsic signaling to tumor microenvironment rewiring.Frontiers in immunology · 2026Review
- Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy.Molecular cancer · 2025Review
- Innovative approaches to CAR-T cell therapy: the role of lipid metabolism pathways.Journal of translational medicine · 2025Review
- Library-based single-cell analysis of CAR signaling reveals drivers of in vivo persistence.Cell systems · 2025Article
- Development and optimization of Eva1 (Journal for immunotherapy of cancer · 2025Article
- Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy.Journal for immunotherapy of cancer · 2025Article
- Dissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screens and single-cell sequencing.Science advances · 2025Article
- Single-Cell Sequence and Machine Learning Identify a CD79A+B Cells-Related Transcriptional Signature for Predicting Clinical Outcomes and Immune Microenvironment in Breast Cancer.Cancer informatics · 2025Article
- Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway.Nature communications · 2024Article
- Integration of transcriptional and epigenetic regulation of TFEB reveals its dual functional roles in Pan-cancer.NAR cancer · 2024Article
- Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies.Journal of hematology & oncology · 2024Review
- Generation ofHeliyon · 2024Article
- Unlocking Apoptotic Pathways: Overcoming Tumor Resistance in CAR-T-Cell Therapy.Cancer medicine · 2024Review
- Co-stimulation of CD28/CD40 signaling molecule potentiates CAR-T cell efficacy and stemness.Molecular therapy. Oncology · 2024Article
- CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.Clinical reviews in allergy & immunology · 2024Review
- NF-κB in biology and targeted therapy: new insights and translational implications.Signal transduction and targeted therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptively transferred CD19 chimeric antigen receptor (CAR) T cells have led to impressive clinical outcomes in B cell malignancies. Beyond induction of remission, the persistence of CAR-T cells is required to prevent relapse and provide long-term disease control. To improve CAR-T cell function and persistence, we developed a composite co-stimulatory domain of a B cell signaling moiety, CD79A/CD40, to induce a nuclear translocating signal, NF-κB, to synergize with other T cell signals and improve CAR-T cell function. CD79A/CD40 incorporating CD19CAR-T cells (CD19.79a.40z) exhibited higher NF-κB and p38 activity upon CD19 antigen exposure compared with the CD28 or 4-1BB incorporating CD19CAR-T cells (CD19.28z and CD19.BBz). Notably, we found that CD19.79a.40z CAR-T cells continued to suppress CD19
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.